Navigation Links
Netsmart Names Dr. Ian Chuang Senior Vice President, Healthcare Informatics and Chief Medical Officer
Date:5/6/2013

Overland Park, Kan (PRWEB) May 06, 2013

Netsmart, the leading provider of clinical solutions for health and human services organizations nationwide, further advanced its clinical and integrated care knowledge base with the addition of Ian Chuang, M.D., M.S., F.C.F.P. as senior vice president, healthcare informatics and chief medical officer.

“Dr. Chuang’s background in physical health and expertise in clinical data and information management is an ideal combination as we help our clients optimize the effectiveness and broaden the scope of care they provide in the coordinated care environment,” said Michael Valentine, chief executive officer, Netsmart.

“Healthcare must improve outside the walls of traditional medical environments,” said Dr. Chuang. “Netsmart is committed to helping its clients in new ways -- mobile solutions, physical health integration, Points of View (POVs) and other innovations to help providers furnish recovery-based care. I’m excited to join the company that is forging the path to the future for its clients while at the same time providing them with tools they need to furnish high quality care today. I don’t believe we can completely impact and improve on physical health without addressing the overlapping impact of behavioral health on the individual.”

Dr. Chuang joins Netsmart from Lockton Benefit Group in Kansas City, Mo., where he served as senior vice president, health risk management. He previously led the development of care management and clinical decision support systems at CIGNA Corporation. Prior to that, he was a director and vice president at Cerner Corporation, where he led initiatives ranging from a systems-based care transformation service with focus on evidence-based practice to a next-generation CDS system with context-sensitive clinical information presentation and viewing.

He has also held clinical
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Mesothelioma Victims Center Now Urges Mesothelioma Victims To Call Them for the Names of the Most Experienced Mesothelioma Lawyers For Much Better Compensation Results
2. US Drug Watchdog Now Urges Transvaginal Mesh Victims Who Have Erosion To Call Them Immediately For The Names Of The Very Skilled Lawyers--Who Will All Be Women
3. US Drug Watchdog Is Expanding Their Transvaginal Mesh Failure Initiative And They Are Urging Victims To Call Them For The Names Of The Best Possible Women Lawyers To Help
4. Mesothelioma Victims Center Urges Retired Shipyard Workers Diagnosed With Mesothelioma To Call Them For The Names Of The Most Experienced Mesothelioma Lawyers-Nationwide
5. The Mesothelioma Victims Center Now Urges US Navy Veterans Diagnosed with Mesothelioma To Call Them For The Names Of The Most Skilled Mesothelioma Lawyers-Compensation
6. US Drug Watchdog Now Urges Victims Of An Unsuccessful Transvaginal Mesh Revision Surgery Nationwide To Call Them For The Names Of The Best Lawyers-Who Will All Be Women
7. Mesothelioma Victims Center Now Urges All Victims Of Mesothelioma Or Their Families To Call Them For The Names Of The Best Mesothelioma Law Firms-Get Better Compensation
8. Mesothelioma Victims Center Now Urges Retired Industrial Workers Diagnosed With Mesothelioma To Call Them For The Names The Best Mesothelioma Law Firms-Quality Matters
9. US Drug Watchdog Now Urges Victims Of A Severe Transvaginal Mesh Implant Failure To Call Them For The Names Of National Caliber Women Attorneys-Get Compensated
10. Mesothelioma Victims Center Now Urges All Victims of Mesothelioma to Call Them for Names Of The Most Experienced Mesothelioma Lawyers-For Better Financial Compensation
11. US Drug Watchdog Now Urges Victims Of A Transvaginal Mesh Failure Who Have Developed Severe Complications To Call Them For The Names Of Top Women Lawyers In The Nation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... about the brain affect the course of a criminal trial, ... a sentence? This was the topic of ... for Neuroscience,s "Neuroscience 2011." Titled "The Brain on Trial: Neuroscience ... neuroscience are both challenging and assisting the judicial system. To ...
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... SAN DIEGO - A new, targeted approach to treating ... Phase I/II clinical trial for patients with relapsed or ... of the American Society of Hematology. "PCI-32765, one ... cell receptor inhibitors, has shown impressive potential in this ...
... FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is easy ... your health during the flu season, but too few Americans ... off concerns about the flu, yet every year it strikes ... to the hospital and killing thousands," Dr. Thomas Slama, president ...
... Terrorist attacks with chemical weapons are a real possibility, ... access journal, Journal of Pharmacy Practice , published by ... how to treat those who have been exposed, pharmacists are ... potential chemical weapons attack. Chemical weapons act on their ...
Cached Medicine News:Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 2Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 3Health News:B cell receptor inhibitor causes chronic lymphocytic leukemia remission 2Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Pharmacists crucial in plan for terrorist chemical weapons 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Company remains committed to speeding innovation ... pipeline boasts 70 potential medicines in clinical development, including 33 in ... ten potential new medicines in Phase III by the end of ... such as neuroscience, diabetes and oncology, as well as new areas ...
... MISSISSAUGA, Ontario, June 30, 2011 Valeant Pharmaceuticals ... VRX) announced today that its subsidiary, Valeant International ... acquire rights to both Elidel (pimecrolimus 1% cream) ... Meda, an international specialty pharmaceutical company (listed on ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 2Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: